Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment.[8] T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor. The resulting chimeric antigen receptor T cells (CAR-Ts) that react to the cancer are then given back to the person to populate the bone marrow.[9] Axicabtagene treatment carries a risk for cytokine release syndrome (CRS) and neurological toxicities.[9]
Due to CD19 being a pan-B cell marker,[10] the T-cells that are engineered to target CD19 receptors on the cancerous B cells[9] also influence normal B cells, except some plasma cells.[11]
^ ab"T Cells - Axicabtagene ciloleucel, cryopreserved - T - Yescarta (axicabtagene ciloleucel) Suspension for Intravenous Infusion". Therapeutic Goods Administration (TGA). Archived from the original on 5 December 2023. Retrieved 16 September 2020.
^"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^"Summary Basis of Decision (SBD) for Yescarta". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
^"Yescarta- axicabtagene ciloleucel suspension". DailyMed. 31 January 2022. Archived from the original on 5 March 2022. Retrieved 4 April 2022.
^Cite error: The named reference FDA Yescarta was invoked but never defined (see the help page).
^"Yescarta EPAR". European Medicines Agency. 16 December 2014. Archived from the original on 28 December 2023. Retrieved 27 February 2024.
^Axicabtagene Ciloleucel (Yescarta) for B-Cell Lymphoma Archived 29 November 2022 at the Wayback Machine Med Lett Drugs Ther. 2018 Jul 16;60(1551):e122-123
^ abc"FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma". U.S. Food and Drug Administration (Press release). Archived from the original on 5 March 2022. Retrieved 20 October 2017. This article incorporates text from this source, which is in the public domain.
^Wang K, Wei G, Liu D (November 2012). "CD19: a biomarker for B cell development, lymphoma diagnosis and therapy". Experimental Hematology & Oncology. 1 (1): 36. doi:10.1186/2162-3619-1-36. PMC 3520838. PMID 23210908.
^Halliley JL, Tipton CM, Liesveld J, Rosenberg AF, Darce J, Gregoretti IV, et al. (July 2015). "Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow". Immunity. 43 (1): 132–45. doi:10.1016/j.immuni.2015.06.016. PMC 4680845. PMID 26187412.
and 29 Related for: Axicabtagene ciloleucel information
Axicabtageneciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional...
for B-cell precursor acute lymphoblastic leukemia (B-ALL), and axicabtageneciloleucel (Yescarta), marketed by Kite Pharma originally for diffuse large...
immunotherapies. The first 2 adoptive T-cell therapies, tisagenlecleucel and axicabtageneciloleucel, were approved by the FDA in 2017. Another approach is adoptive...
its annual list of the preceding year's 50 Smartest Companies. Axicabtageneciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for...
approved in the United States. In October, a similar therapy called axicabtageneciloleucel was approved for non-Hodgkin lymphoma. In October, biophysicist...
identical to those of the REMS Program for another CAR-T therapy, axicabtageneciloleucel (Yescarta). Brexucabtagene autoleucel was approved for medical...
refractory large B-cell lymphoma with two failed systemic treatments), axicabtageneciloleucel, tisagenlecleucel (for large B-cell lymphoma), and brexucabtagene...
October 2017. In October 2017, Kite Pharma's therapy, Yescarta (axicabtageneciloleucel) became the first CAR-T therapy approved by the FDA for the treatment...
Global Information
This article incorporates text from this source, which is in the public domain.
